Company Encyclopedia
View More
name
Spectral AI
MDAI.US
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc.
1.391 T
MDAI.USMarket value -Rank by Market Cap -/-

Financial Score

15/11/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking89/170
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE261.03%A
    • Profit Margin-70.64%E
    • Gross Margin42.75%B
  • Growth ScoreD
    • Revenue YoY-15.02%E
    • Net Profit YoY-47.18%D
    • Total Assets YoY31.87%A
    • Net Assets YoY-89.18%E
  • Cash ScoreD
    • Cash Flow Margin-141.57%D
    • OCF YoY-15.02%E
  • Operating ScoreA
    • Turnover1.72A
  • Debt ScoreE
    • Gearing Ratio153.61%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MDAI: Looking Ahead to 1H:26 DeepView Clearance

    Spectral AI, Inc. (NASDAQ:MDAI) announced its third quarter earnings on November 11th. Key developments include presentations at the European Burns Association Congress, recognition by Time Magazine as a top HealthTech company, and securing $7.6 million in additional capital. However, research and development revenues have declined sequentially.

    MSN·
    US
    MDAI
    -7.88%
    MSN·
    US
    MDAI
    -7.88%

    Spectral AI Earnings Call: Mixed Sentiment and Future Growth

    Spectral AI, Inc. held its Q3 earnings call, revealing mixed sentiment. The company has a strong cash position of $10.5 million and positive international feedback for its DeepView system, but faces challenges with a decline in R&D revenue, increased net loss of $3.6 million, and reduced 2025 revenue guidance from $21.5 million to $18.5 million. Despite these hurdles, Spectral AI remains optimistic about future growth, particularly in 2027 and 2028, while focusing on commercialization efforts and product development.

    Tip Ranks·
    US
    MDAI
    -7.88%
    Tip Ranks·
    US
    MDAI
    -7.88%

    Northland Securities Keeps Their Buy Rating on Spectral AI (MDAI)

    Northland Securities has maintained a Buy rating on Spectral AI (MDAI) with a price target of $6.00, as reported by Carl Byrnes. Additionally, BTIG also holds a Buy rating for the stock, setting a price target of $3.00. Byrnes focuses on the Healthcare sector and has an average return of -4.1% with a 36.78% success rate on his stock recommendations.

    Tip Ranks·
    US
    MDAI
    -7.88%
    Tip Ranks·
    US
    MDAI
    -7.88%

    Spectral AI’s Long-Term Growth Prospects and Strategic Developments Justify Buy Rating Despite Short-Term Setbacks

    Spectral AI, a healthcare company, received a Buy rating from analyst Ryan Zimmerman of BTIG, with a price target of $3.00. Despite reporting lower-than-expected revenue and earnings for Q3 2025 due to a government contract's timing and a government shutdown, long-term growth prospects remain strong. Key milestones include FDA regulatory filings and a planned spin-off of its IP subsidiary. The anticipated commercial launch of the DeepView system is expected to drive significant revenue growth in the coming years, justifying the Buy rating.

    Tip Ranks·
    US
    MDAI
    -7.88%
    Tip Ranks·
    US
    MDAI
    -7.88%

    Spectral AI reports Q3 research and development revenue of $3.8 million

    Spectral AI, Inc. reported Q3 research and development revenue of $3.8 million for the quarter ending September 30, 2025, down from $8.2 million in Q3 2024. Year-to-date revenue was $15.6 million, compared to $22.0 million the previous year. The company achieved a gross profit of $1.6 million for Q3 and $7.1 million for the first nine months of 2025. Cash on hand increased to $10.5 million from $3.7 million a year earlier. Spectral AI is progressing towards its De Novo FDA submission and focusing on commercializing its AI-driven diagnostic device.

    Reuters·
    US
    MDAI
    -7.88%
    Reuters·
    US
    MDAI
    -7.88%